Chelsea Counsel Company’s Novo Nordisk NVO Stock Holding History

Chelsea Counsel Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19K	Hold	500	–	–	0.01%	165
2025 Q4	$25.4K	Hold	500	–	–	0.01%	150
2025 Q3	$27.7K	Hold	500	–	–	0.01%	153
2025 Q2	$34.5K	Hold	500	–	–	0.02%	148
2025 Q1	$35.3K	Hold	500	–	–	0.02%	146
2024 Q4	$43K	Hold	500	–	–	0.02%	136
2024 Q3	$59.5K	Hold	500	–	–	0.03%	131
2024 Q2	$71.4K	Buy	+500	New	+$66.3K	0.04%	116

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Chelsea Counsel Company's NVO Position: Q1 2026 in Review

Chelsea Counsel Company held its Novo Nordisk (NVO) position steady in Q1 2026 at 500 shares worth $19K. The position accounts for 0.01% of the portfolio, ranked #165.

Chelsea Counsel Company first reported a position in NVO in Q2 2024 and has held it in 8 quarters since. The position peaked at $71.4K in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Chelsea Counsel Company held 500 shares of Novo Nordisk worth $19K as of Q1 2026.
Chelsea Counsel Company left its Novo Nordisk share count unchanged in Q1 2026.
Novo Nordisk made up 0.01% of Chelsea Counsel Company's portfolio in Q1 2026, its #165 holding.
Chelsea Counsel Company first reported a position in Novo Nordisk in Q2 2024 and has held it in 8 quarters since.
Chelsea Counsel Company's Novo Nordisk position peaked at $71.4K in Q2 2024.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Chelsea Counsel Company's 13F filing for Q1 2026, filed 24 Apr 2026.